PubMed

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.

Raftery J, Clegg A, Jones J, Tan SC, Lotery A.

Br J Ophthalmol. 2007 Sep;91(9):1244-6. Epub 2007 Apr 12.PMID: 17431015 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.PMID: 18462575 [PubMed - indexed for MEDLINE]Related articlesFree article

[Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration]

Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.

Klin Monbl Augenheilkd. 2007 Sep;224(9):727-32. German. PMID: 17846963 [PubMed - indexed for MEDLINE]Related articles

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.

Brown MM, Brown GC, Brown HC, Peet J.

Ophthalmology. 2008 Jun;115(6):1039-1045.e5. Epub 2007 Nov 5.PMID: 17976724 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

Clin Ther. 2008 Dec;30(12):2436-51.PMID: 19167602 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.PMID: 17887807 [PubMed - indexed for MEDLINE]Related articles

[The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes]

Karel I.

Cesk Slov Oftalmol. 2007 Sep;63(5):311-9. Czech. PMID: 17915581 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S.

Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.PMID: 18035208 [PubMed - indexed for MEDLINE]Related articles

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.

Ophthalmology. 2001 Nov;108(11):2051-9.PMID: 11713079 [PubMed - indexed for MEDLINE]Related articles

Computerized model of cost-utility analysis for treatment of age-related macular degeneration.

Fletcher EC, Lade RJ, Adewoyin T, Chong NV.

Ophthalmology. 2008 Dec;115(12):2192-8. Epub 2008 Oct 18.PMID: 18930556 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

Value Health. 2008 Jul-Aug;11(4):563-74. Epub 2007 Dec 17.PMID: 18179676 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

Cohen SY, Bremond-Gignac D, Quentel G, Mimoun G, Citterio T, Bisot-Locard S, Beresniak A.

Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1527-34. Epub 2008 Jul 19.PMID: 18642019 [PubMed - indexed for MEDLINE]Related articles

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Hopley C, Salkeld G, Mitchell P.

Br J Ophthalmol. 2004 Aug;88(8):982-7.PMID: 15258009 [PubMed - indexed for MEDLINE]Related articlesFree article

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.PMID: 17346499 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.

Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.

Graefes Arch Clin Exp Ophthalmol. 2009 Aug 11. [Epub ahead of print]PMID: 19669678 [PubMed - as supplied by publisher]Related articles

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.

Brown GC, Brown MM, Campanella J, Beauchamp GR.

Am J Ophthalmol. 2005 Oct;140(4):679-87.PMID: 16226519 [PubMed - indexed for MEDLINE]Related articles

Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS.

Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002. Review.PMID: 19476398 [PubMed - indexed for MEDLINE]Related articles

[Lucentis versus Avastin--is there a light at the end of the tunnel for age-related macular degeneration patients?]

Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y.

Harefuah. 2008 Jul;147(7):605-6, 662. Hebrew. PMID: 18814519 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.

Smith DH, Fenn P, Drummond M.

Br J Ophthalmol. 2004 Sep;88(9):1107-12.PMID: 15317697 [PubMed - indexed for MEDLINE]Related articlesFree article

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.

Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D.

Clin Experiment Ophthalmol. 2008 Apr;36(3):252-6.PMID: 18412594 [PubMed - indexed for MEDLINE]Related articles